Adicet Bio Inc Financials
This page shows Adicet Bio Inc (ACET) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Adicet Bio’s business model is still defined by R&D-led cash burn funded through repeated external financing.
From FY2023 to FY2025, operating cash burn stayed near$95M even as net loss improved, so the accounting loss narrowed without a comparable reduction in cash consumption. That mismatch helps explain why cash fell from$159.7M to$38.9M despite sizable financing inflows in recent years.
In FY2025, R&D spending of
Liabilities remain modest at
Financial Health Signals
Adicet Bio Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Adicet Bio Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Adicet Bio Inc reported a net loss of $116.8M while operations used $95.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Adicet Bio Inc reported an operating loss of $122.1M against $36K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Adicet Bio Inc's EBITDA was -$115.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.5% from the prior year.
Adicet Bio Inc reported -$116.8M in net income in fiscal year 2025. This represents an increase of 0.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Adicet Bio Inc recorded an outflow of $97.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 3.7% from the prior year.
Adicet Bio Inc held $38.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Adicet Bio Inc's ROE was -73.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Adicet Bio Inc invested $99.1M in research and development in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Adicet Bio Inc invested $1.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 55.5% from the prior year.
Not reported for fiscal year 2025.
ACET Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $99.1M-0.2% | $99.3M-6.3% | $106.0M+48.8% | $71.2M+45.6% | $48.9M+42.5% | $34.3M+44.9% | $23.7M+61.0% | $14.7M-12.6% | $16.8M |
| SG&A Expenses | N/A | $23.0M-18.8% | $28.3M+6.6% | $26.5M+0.9% | $26.3M+18.3% | $22.2M-2.4% | $22.8M+161.8% | $8.7M+3.1% | $8.4M+312.5% | $2.0M |
| Operating Income | N/A | -$122.1M+4.3% | -$127.6M+16.1% | -$152.0M-109.6% | -$72.6M-18.1% | -$61.4M-56.8% | -$39.2M-24.9% | -$31.4M-109.8% | -$15.0M+20.7% | -$18.9M |
| Interest Expense | N/A | $36K+800.0% | $4K-84.0% | $25K-68.8% | $80K-54.5% | $176K+31.3% | $134K | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0+100.0% | -$125K+95.6% | -$2.8M-14915.8% | $19K+103.2% | -$589K | $0 |
| Net Income | N/A | -$116.8M+0.3% | -$117.1M+17.9% | -$142.7M-104.4% | -$69.8M-12.6% | -$62.0M-69.0% | -$36.7M-30.4% | -$28.1M-202.6% | -$9.3M+72.5% | -$33.8M |
| EPS (Diluted) | — | -$16.95 | -$21.33 | -$3.31-94.7% | -$1.70+15.0% | -$2.00 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACET Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $192.4M-12.7% | $220.2M+6.2% | $207.3M-37.3% | $330.7M-2.4% | $338.9M+120.3% | $153.8M+88.6% | $81.6M-25.8% | $109.9M+99.2% | $55.2M |
| Current Assets | $160.9M-10.7% | $180.1M+11.0% | $162.3M-37.8% | $261.0M-7.6% | $282.4M+181.5% | $100.3M+56.3% | $64.2M-41.4% | $109.5M+98.6% | $55.2M |
| Cash & Equivalents | $38.9M-31.1% | $56.5M-64.6% | $159.7M-38.0% | $257.7M-7.2% | $277.5M+229.1% | $84.3M+695.0% | $10.6M+11.9% | $9.5M-82.2% | $53.3M |
| Goodwill | N/A | N/A | $0-100.0% | $19.5M0.0% | $19.5M-3.1% | $20.1M | N/A | N/A | N/A |
| Total Liabilities | $33.1M-1.4% | $33.6M-9.5% | $37.1M-3.2% | $38.4M+7.1% | $35.8M-18.6% | $44.0M-69.0% | $142.0M-1.0% | $143.5M+74.6% | $82.1M |
| Current Liabilities | $21.5M+11.0% | $19.4M+0.5% | $19.3M-2.1% | $19.7M+20.8% | $16.3M-27.4% | $22.5M+51.2% | $14.9M+160.1% | $5.7M+3.9% | $5.5M |
| Total Equity | $159.2M-14.7% | $186.6M+9.7% | $170.2M-41.8% | $292.3M-3.6% | $303.1M+176.0% | $109.8M+281.9% | -$60.4M-80.1% | -$33.5M-24.4% | -$26.9M |
| Retained Earnings | -$614.7M-23.5% | -$497.9M-30.8% | -$380.8M-59.9% | -$238.1M-41.5% | -$168.3M-58.3% | -$106.3M-52.7% | -$69.6M+2.4% | -$71.4M-111.4% | -$33.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
ACET Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$84.5M | -$95.2M-3.1% | -$92.4M+1.4% | -$93.7M-109.4% | -$44.8M+12.3% | -$51.1M-22.9% | -$41.6M-49.0% | -$27.9M-53.4% | -$18.2M-65.5% | -$11.0M |
| Capital Expenditures | $438K | $1.7M+55.5% | $1.1M-75.0% | $4.5M-73.4% | $16.8M+28.6% | $13.0M+1217.8% | $990K-7.5% | $1.1M+22.1% | $876K+1890.9% | $44K |
| Free Cash Flow | -$85.0M | -$97.0M-3.7% | -$93.5M+4.8% | -$98.2M-59.5% | -$61.5M+4.0% | -$64.1M-50.7% | -$42.5M-46.9% | -$29.0M-51.9% | -$19.1M-72.8% | -$11.0M |
| Investing Cash Flow | $7.8M | $2.4M+102.0% | -$119.2M-2571.2% | -$4.5M+73.4% | -$16.8M-500.2% | -$2.8M-102.4% | $115.2M+340.4% | -$47.9M-198.5% | -$16.1M-36395.5% | -$44K |
| Financing Cash Flow | $75.1M | $75.2M-32.4% | $111.3M+47064.0% | $236K-99.4% | $41.5M-82.9% | $242.7M+79994.1% | $303K-99.6% | $76.9M+596.6% | $11.0M-82.8% | $64.4M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ACET Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -73.4%-10.6pp | -62.8%+21.1pp | -83.8%-60.0pp | -23.9%-3.4pp | -20.4%+13.0pp | -33.4% | N/A | N/A | N/A |
| Return on Assets | -60.7%-7.5pp | -53.2%+15.6pp | -68.8%-47.7pp | -21.1%-2.8pp | -18.3%+5.5pp | -23.8%+10.6pp | -34.5%-26.0pp | -8.5%+52.7pp | -61.2% |
| Current Ratio | 7.47-1.8x | 9.29+0.9x | 8.41-4.8x | 13.25-4.1x | 17.31+12.8x | 4.46+0.1x | 4.32-14.8x | 19.16+9.1x | 10.02 |
| Debt-to-Equity | 0.210.0x | 0.180.0x | 0.22+0.1x | 0.130.0x | 0.12-0.3x | 0.40 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Adicet Bio Inc Ranks
Frequently Asked Questions
Is Adicet Bio Inc profitable?
No, Adicet Bio Inc (ACET) reported a net income of -$116.8M in fiscal year 2025.
What is Adicet Bio Inc's EBITDA?
Adicet Bio Inc (ACET) had EBITDA of -$115.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Adicet Bio Inc's return on equity (ROE)?
Adicet Bio Inc (ACET) has a return on equity of -73.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Adicet Bio Inc's free cash flow?
Adicet Bio Inc (ACET) recorded an outflow of $97.0M in free cash flow during fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Adicet Bio Inc's operating cash flow?
Adicet Bio Inc (ACET) recorded an outflow of $95.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Adicet Bio Inc's total assets?
Adicet Bio Inc (ACET) had $192.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Adicet Bio Inc's capital expenditures?
Adicet Bio Inc (ACET) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Adicet Bio Inc spend on research and development?
Adicet Bio Inc (ACET) invested $99.1M in research and development during fiscal year 2025.
What is Adicet Bio Inc's current ratio?
Adicet Bio Inc (ACET) had a current ratio of 7.47 as of fiscal year 2025, which is generally considered healthy.
What is Adicet Bio Inc's debt-to-equity ratio?
Adicet Bio Inc (ACET) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adicet Bio Inc's return on assets (ROA)?
Adicet Bio Inc (ACET) had a return on assets of -60.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Adicet Bio Inc's cash runway?
Based on fiscal year 2025 data, Adicet Bio Inc (ACET) had $38.9M in cash against an annual operating cash burn of $95.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Adicet Bio Inc's Piotroski F-Score?
Adicet Bio Inc (ACET) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adicet Bio Inc's earnings high quality?
Adicet Bio Inc (ACET) reported a net loss of $116.8M while operations used $95.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Adicet Bio Inc cover its interest payments?
Adicet Bio Inc (ACET) reported an operating loss of $122.1M against $36K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.